We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » ARIZONA LAWMAKERS SEEK MEDICARE POLICY SHIFT ON URINARY CATHETER REUSE

ARIZONA LAWMAKERS SEEK MEDICARE POLICY SHIFT ON URINARY CATHETER REUSE

July 6, 2006

Two House lawmakers are challenging a Medicare policy they say forces patients suffering from bladder dysfunctions to reuse urinary catheters.

Catheters are narrow tubes inserted through the urethra to drain the bladder. Infection risks increase with reuse of the devices, which are labeled for single use only by the FDA, according to a letter drafted by Reps. Rick Renzi (R.-Ariz.) and J.D. Hayworth (R-Ariz.) to Mark McClellan, administrator of the Centers for Medicare and Medicaid (CMS).

Medicare currently pays for only one catheter per week for outpatients, "except under very limited circumstances" for nursing home patients, those with systems that are immunosuppressed and pregnant women with spinal cord injuries, the congressmen noted.

The current policy is the result of a local coverage decision (LCD) and not a national coverage decision, a CMS spokewoman said. "This LCD is not an absolute bar to single use, but there has to be some reason medically having do with a particular patient" to change the policy on an individual basis.

A review of CMS literature shows that "clean, intermittent catheterization has been accepted as safe for over 24 years," she added.

KEYWORDS FDAnews Device Daily Bulletin

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 13Jul

    FDA Ad and Promo Enforcement Trends: Past, Present and Future

  • 28Jul

    EU-MDR’s Growing Pains: Are You Current with the Latest Developments?

  • 28Jul

    Is Your Product a Drug or Device — and Does It Matter?: A Recent Appeals Court Decision Says It Does

  • 02Aug

    Medical Device Cybersecurity: Understand the Latest Developments

  • 03Aug

    Pharmaceutical Process Validation: Best Practices for Success

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Okami Medical’s LOBO-7 and LOBO-9 Vascular Occluders Cleared

  • FDA Puts Clinical Hold on Astellas Late-Onset Pompe Disease Clinical Trial

  • FDA Provides Update on GE Healthcare’s Recall of Its Carescape R860 Ventilators

  • Gilead Resubmits NDA for Lenacapavir Following Complete Response Letter

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing